OneChain Immunotherapeutics is developing CAR-T cell therapies specifically targeting hematological malignancies, including cortical T-cell acute lymphoblastic leukemia (coT-ALL). Their biomedicines aim to provide effective immunotherapy options for patients with these challenging oncological diseases.
Funding
$10.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hematological malignancies, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), present significant treatment challenges and often have limited effective immunotherapy options. Current treatments may be ineffective or have severe side effects, leaving a critical unmet need for targeted therapies.
Solution
OneChain Immunotherapeutics is developing CAR-T cell therapies specifically engineered to target hematological malignancies. Their approach involves modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that recognizes and binds to specific proteins on cancer cells. This engineered CAR-T cell then selectively targets and destroys cancer cells expressing the target antigen. By precisely targeting cancer cells, OneChain's CAR-T therapies aim to provide effective immunotherapy options while minimizing off-target effects and improving patient outcomes. The company is focused on developing novel CAR-T candidates for oncological diseases with high unmet needs.
Target Audience
The primary target audience includes patients with hematological malignancies, particularly those with cortical T-cell acute lymphoblastic leukemia (coT-ALL), who have limited treatment options or have relapsed after standard therapies, as well as the hematologists and oncologists who treat them.
Features
- CAR-T cell therapy targeting specific antigens expressed on hematological malignancies.
- Utilizes a patient's own T cells, modified ex vivo to express a CAR.
- Designed for precise targeting of cancer cells, minimizing off-target effects.
- Focus on cortical T-cell acute lymphoblastic leukemia (coT-ALL) and other challenging oncological diseases.